Korean J healthc assoc Infect Control Prev.  2022 Jun;27(1):4-17. 10.14192/kjicp.2022.27.1.4.

Detection and Control of Candida auris in Healthcare Settings

• Kwon YJ
• Shin JH

• KMID: 2530821
• DOI: http://doi.org/10.14192/kjicp.2022.27.1.4

Abstract

Since it was first reported in 2009 after isolation from ear cultures of 1 Japanese patient and 15 Korean patients, Candida auris infections have been reported in at least 35 countries on 6 continents. The global emergence of C. auris raises several serious concerns for public health due to the high rates of antifungal drug resistance, organism misidentification, and high transmissibility among hospitalised patients, leading to nosocomial outbreaks and significant patient mortality. Furthermore, during the last 10 years, outbreaks or invasive healthcare-associated infections due to C. auris have been frequently reported in many countries, highlighting that adequate laboratory capacity and infection control preparedness are required to prevent spread within hospitals.

Keyword

Candida auris; Infection control; Antifungal drug resistance; Outbreaks

Figure

• 

  Fig. 1 Flowchart of screening test of C. auris colonization in healthcare facility.

Reference

1. Kim MN, Shin JH, Sung H, Lee K, Kim EC, Ryoo N, et al. 2009; Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features. Clin Infect Dis. 48:e57–61. DOI: 10.1086/597108. PMID: 19193113.

2. Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. 2009; Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 53:41–4. Erratum in: Microbiol Immunol 2018;62: 205. DOI: 10.1111/j.1348-0421.2008.00083.x. PMID: 19161556.

3. Chowdhary A, Sharma C, Duggal S, Agarwal K, Prakash A, Singh PK, et al. 2013; New clonal strain of Candida auris, Delhi, India. Emerg Infect Dis. 19:1670–3. DOI: 10.3201/eid1910.130393. PMID: 24048006. PMCID: PMC3810747.

4. Chowdhary A, Anil Kumar V, Sharma C, Prakash A, Agarwal K, Babu R, et al. 2014; Multidrug-resistant endemic clonal strain of Candida auris in India. Eur J Clin Microbiol Infect Dis. 33:919–26. DOI: 10.1007/s10096-013-2027-1. PMID: 24357342.

5. Calvo B, Melo AS, Perozo-Mena A, Hernandez M, Francisco EC, Hagen F, et al. 2016; First report of Candida auris in America: clinical and microbiological aspects of 18 episodes of candidemia. J Infect. 73:369–74. DOI: 10.1016/j.jinf.2016.07.008. PMID: 27452195.

6. Schelenz S, Hagen F, Rhodes JL, Abdolrasouli A, Chowdhary A, Hall A, et al. 2016; First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control. 5:35. DOI: 10.1186/s13756-016-0132-5. PMID: 27777756. PMCID: PMC5069812.

7. Chowdhary A, Prakash A, Sharma C, Kordalewska M, Kumar A, Sarma S, et al. 2018; A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J Antimicrob Chemother. 73:891–9. DOI: 10.1093/jac/dkx480. PMID: 29325167.

8. Lee WG, Shin JH, Uh Y, Kang MG, Kim SH, Park KH, et al. 2011; First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol. 49:3139–42. DOI: 10.1128/JCM.00319-11. PMID: 21715586. PMCID: PMC3165631.

9. Govender NP, Magobo RE, Mpembe R, Mhlanga M, Matlapeng P, Corcoran C, et al. 2018; Candida auris in South Africa, 2012-2016. Emerg Infect Dis. 24:2036–40. DOI: 10.3201/eid2411.180368. PMID: 30334713. PMCID: PMC6200016.

10. Du H, Bing J, Hu T, Ennis CL, Nobile CJ, Huang G. 2020; Candida auris: epidemiology, biology, antifungal resistance, and virulence. PLoS Pathog. 16:e1008921. DOI: 10.1371/journal.ppat.1008921. PMID: 33091071. PMCID: PMC7581363.

11. Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, et al. 2017; Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis. 64:134–40. Erratum in: Clin Infect Dis 2018;67:987. DOI: 10.1093/cid/ciw691. PMID: 27988485. PMCID: PMC5215215.

12. Ben-Ami R, Berman J, Novikov A, Bash E, Shachor-Meyouhas Y, Zakin S, et al. 2017; Multidrug-resistant Candida haemulonii and C. auris, Tel Aviv, Israel. Emerg Infect Dis. 23:195–203. DOI: 10.3201/eid2302.161486. PMID: 28098529. PMCID: PMC5324804.

13. Welsh RM, Bentz ML, Shams A, Houston H, Lyons A, Rose LJ, et al. 2017; Survival, persistence, and isolation of the emerging multidrug-resistant pathogenic yeast Candida auris on a plastic health care surface. J Clin Microbiol. 55:2996–3005. DOI: 10.1128/JCM.00921-17. PMID: 28747370. PMCID: PMC5625385.

14. Adams E, Quinn M, Tsay S, Poirot E, Chaturvedi S, Southwick K, et al. 2018; Candida auris in healthcare facilities, New York, USA, 2013-2017. Emerg Infect Dis. 24:1816–24. DOI: 10.3201/eid2410.180649. PMID: 30226155. PMCID: PMC6154128.

15. Armstrong PA, Rivera SM, Escandon P, Caceres DH, Chow N, Stuckey MJ, et al. 2019; Hospital-associated multicenter outbreak of emerging fungus Candida auris, Colombia, 2016. Emerg Infect Dis. 25:1339–46. DOI: 10.3201/eid2507.180491. PMID: 31211679. PMCID: PMC6590770.

16. Mulet Bayona JV, Tormo Palop N, Salvador García C, Herrero Rodríguez P, Ferrer Gómez C, et al. Abril López de Medrano V. 2020; Characteristics and management of candidaemia episodes in an established Candida auris outbreak. Antibiotics (Basel). 9:558. DOI: 10.3390/antibiotics9090558. PMID: 32872580. PMCID: PMC7559407.

17. Rudramurthy SM, Chakrabarti A, Paul RA, Sood P, Kaur H, Capoor MR, et al. 2017; Candida auris candidaemia in Indian ICUs: analysis of risk factors. J Antimicrob Chemother. 72:1794–801. DOI: 10.1093/jac/dkx034. PMID: 28333181.

18. Ruiz-Gaitán A, Martínez H, Moret AM, Calabuig E, Tasias M, Alastruey-Izquierdo A, et al. 2019; Detection and treatment of Candida auris in an outbreak situation: risk factors for developing colonization and candidemia by this new species in critically ill patients. Expert Rev Anti Infect Ther. 17:295–305. DOI: 10.1080/14787210.2019.1592675. PMID: 30922129.

19. Ruiz-Gaitán A, Moret AM, Tasias-Pitarch M, Aleixandre-López AI, Martínez-Morel H, Calabuig E, et al. 2018; An outbreak due to Candida auris with prolonged colonisation and candidaemia in a tertiary care European hospital. Mycoses. 61:498–505. DOI: 10.1111/myc.12781. PMID: 29655180.

20. Shastri PS, Shankarnarayan SA, Oberoi J, Rudramurthy SM, Wattal C, Chakrabarti A. 2020; Candida auris candidaemia in an intensive care unit - prospective observational study to evaluate epidemiology, risk factors, and outcome. J Crit Care. 57:42–8. DOI: 10.1016/j.jcrc.2020.01.004. PMID: 32062286.

21. Caceres DH, Rivera SM, Armstrong PA, Escandon P, Chow NA, Ovalle MV, et al. 2020; Case-case comparison of Candida auris versus other Candida species bloodstream infections: results of an outbreak investigation in Colombia. Mycopathologia. 185:917–23. DOI: 10.1007/s11046-020-00478-1. PMID: 32860564.

22. Centers for Disease Control. Infection prevention and control for Candida auris. https://www.cdc.gov/fungal/candida-auris/c-auris-infection-control.html. (Updated on 19 July 2021).

23. European Centre for Disease Prevention. Candida auris in healthcare settings - Europe. https://www.ecdc.europa.eu/sites/default/files/documents/RRA-Candida-auris-European-Union-countries.pdf. (Updated on 23 April 2018).

24. Public Health England. Guidance for the laboratory investigation, management and infection prevention and control for cases of Candida auris v2.0. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/637685/Updated_Candida_auris_Guidance_v2.pdf. (Updated on August 2017).

25. Queensland Health. Guideline for infection prevention and control of Candida auris. https://www.health.qld.gov.au/__data/assets/pdf_file/0028/722827/Candida-auris-guideline.pdf. (Updated on January 2019).

26. Kwon YJ, Shin JH, Byun SA, Choi MJ, Won EJ, Lee D, et al. 2019; Candida auris clinical isolates from South Korea: identification, antifungal susceptibility, and genotyping. J Clin Microbiol. 57:e01624–18. DOI: 10.1128/JCM.01624-18. PMID: 30728190. PMCID: PMC6440790.

27. Jung J, Kim MJ, Kim JY, Lee JY, Kwak SH, Hong MJ, et al. 2020; Candida auris colonization or infection of the ear: a single-center study in South Korea from 2016 to 2018. Med Mycol. 58:124–7. DOI: 10.1093/mmy/myz020. PMID: 30874806.

28. Welsh RM, Sexton DJ, Forsberg K, Vallabhaneni S, Litvintseva A. 2019; Insights into the unique nature of the East Asian clade of the emerging pathogenic yeast Candida auris. J Clin Microbiol. 57:e00007–19. DOI: 10.1128/JCM.00007-19. PMID: 30760535. PMCID: PMC6440783.

29. Emara M, Ahmad S, Khan Z, Joseph L, Al-Obaid I, Purohit P, et al. 2015; Candida auris candidemia in Kuwait, 2014. Emerg Infect Dis. 21:1091–2. DOI: 10.3201/eid2106.150270. PMID: 25989098. PMCID: PMC4451886.

30. Adam RD, Revathi G, Okinda N, Fontaine M, Shah J, Kagotho E, et al. 2019; Analysis of Candida auris fungemia at a single facility in Kenya. Int J Infect Dis. 85:182–7. DOI: 10.1016/j.ijid.2019.06.001. PMID: 31185293.

31. Sayeed MA, Farooqi J, Jabeen K, Awan S, Mahmood SF. 2019; Clinical spectrum and factors impacting outcome of Candida auris: a single center study from Pakistan. BMC Infect Dis. 19:384. DOI: 10.1186/s12879-019-3999-y. PMID: 31060514. PMCID: PMC6501321.

32. Sayeed MA, Farooqi J, Jabeen K, Mahmood SF. 2020; Comparison of risk factors and outcomes of Candida auris candidemia with non-Candida auris candidemia: a retrospective study from Pakistan. Med Mycol. 58:721–9. DOI: 10.1093/mmy/myz112. PMID: 31773169.

33. Ahmad S, Khan Z, Al-Sweih N, Alfouzan W, Joseph L. 2020; Candida auris in various hospitals across Kuwait and their susceptibility and molecular basis of resistance to antifungal drugs. Mycoses. 63:104–12. DOI: 10.1111/myc.13022. PMID: 31618799.

34. Alfouzan W, Ahmad S, Dhar R, Asadzadeh M, Almerdasi N, Abdo NM, et al. 2020; Molecular epidemiology of Candida auris outbreak in a major secondary-care hospital in Kuwait. J Fungi (Basel). 6:307. DOI: 10.3390/jof6040307. PMID: 33233388. PMCID: PMC7712429.

35. Magobo R, Mhlanga M, Corcoran C, Govender NP. 2020; Multilocus sequence typing of azole-resistant Candida auris strains, South Africa. S Afr J Infect Dis. 35:116. DOI: 10.4102/sajid.v35i1.116. PMID: 34485470. PMCID: PMC8378186.

36. Chow NA, Gade L, Tsay SV, Forsberg K, Greenko JA, Southwick KL, et al. 2018; Multiple introductions and subsequent transmission of multidrug-resistant Candida auris in the USA: a molecular epidemiological survey. Lancet Infect Dis. 18:1377–84. DOI: 10.1016/S1473-3099(18)30597-8. PMID: 30293877. PMCID: PMC6556114.

37. Zhu Y, O'Brien B, Leach L, Clarke A, Bates M, Adams E, et al. 2020; Laboratory analysis of an outbreak of Candida auris in New York from 2016 to 2018: impact and lessons learned. J Clin Microbiol. 58:e01503-19. DOI: 10.1128/JCM.01503-19. PMID: 31852764. PMCID: PMC7098748.

38. Naicker SD, Maphanga TG, Chow NA, Allam M, Kwenda S, Ismail A, et al. 2021; Clade distribution of Candida auris in South Africa using whole genome sequencing of clinical and environmental isolates. Emerg Microbes Infect. 10:1300–8. DOI: 10.1080/22221751.2021.1944323. PMID: 34176429. PMCID: PMC8253216.

39. Chow NA, de Groot T, Badali H, Abastabar M, Chiller TM, Meis JF. 2019; Potential fifth clade of Candida auris, Iran, 2018. Emerg Infect Dis. 25:1780–1. DOI: 10.3201/eid2509.190686. PMID: 31310230. PMCID: PMC6711235.

40. Kwon YJ, Byun SA, Choi MJ, Won EJ, Kim SH, Shin JH. 2019; Species distribution and antifungal susceptibility of yeasts isolated from ear specimens. Ann Clin Microbiol. 22:81–9. DOI: 10.5145/ACM.2019.22.4.81.

41. Ma T, In YH, Byun SA, Lee GY, Choi MJ, Lee SY, et al. 2022; Identification of Candida auris and closely related species using a new matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, the ASTA MicroIDSys System. Lab Med Online. 12:40–5. DOI: 10.47429/lmo.2022.12.1.40.

42. Centers for Disease Control. Identification of Candida auris. https://www.cdc.gov/fungal/candida-auris/identification.html. (Updated on 29 May 2020).

43. Bao JR, Master RN, Azad KN, Schwab DA, Clark RB, Jones RS, et al. 2018; Rapid, accurate identification of Candida auris by using a novel matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) database (library). J Clin Microbiol. 56:e01700–17. DOI: 10.1128/JCM.01700-17. PMID: 29367296. PMCID: PMC5869814.

44. Vatanshenassan M, Boekhout T, Meis JF, Berman J, Chowdhary A, Ben-Ami R, et al. 2019; Candida auris identification and rapid antifungal susceptibility testing against echinocandins by MALDI-TOF MS. Front Cell Infect Microbiol. 9:20. DOI: 10.3389/fcimb.2019.00020. PMID: 30834236. PMCID: PMC6387932.

45. Ambaraghassi G, Dufresne PJ, Dufresne SF, Vallières É, Muñoz JF, Cuomo CA, et al. 2019; Identification of Candida auris by use of the updated Vitek 2 yeast identification system, version 8.01: a multilaboratory evaluation study. J Clin Microbiol. 57:e00884–19. DOI: 10.1128/JCM.00884-19. PMID: 31413079. PMCID: PMC6812989.

46. Dennis EK, Chaturvedi S, Chaturvedi V. 2021; So many diagnostic tests, so little time: review and preview of Candida auris testing in clinical and public health laboratories. Front Microbiol. 12:757835. DOI: 10.3389/fmicb.2021.757835. PMID: 34691009. PMCID: PMC8529189.

47. Centers for Disease Control. Antifungal susceptibility testing and interpretation. https://www.cdc.gov/fungal/candida-auris/c-auris-antifungal.html. (Updated on 29 May 2020).

48. Eyre DW, Sheppard AE, Madder H, Moir I, Moroney R, Quan TP, et al. 2018; A Candida auris outbreak and its control in an intensive care setting. N Engl J Med. 379:1322–31. DOI: 10.1056/NEJMoa1714373. PMID: 30281988.

49. Khan Z, Ahmad S, Al-Sweih N, Joseph L, Alfouzan W, Asadzadeh M. 2018; Increasing prevalence, molecular characterization and antifungal drug susceptibility of serial Candida auris isolates in Kuwait. PLoS One. 13:e0195743. DOI: 10.1371/journal.pone.0195743. PMID: 29630658. PMCID: PMC5891028.

50. Escandón P, Cáceres DH, Espinosa-Bode A, Rivera S, Armstrong P, Vallabhaneni S, et al. 2018; Notes from the field: surveillance for Candida auris - Colombia, September 2016-May 2017. MMWR Morb Mortal Wkly Rep. 67:459–60. DOI: 10.15585/mmwr.mm6715a6. PMID: 29672473. PMCID: PMC6191104.

51. Ostrowsky B, Greenko J, Adams E, Quinn M, O'Brien B, Chaturvedi V, et al. 2020; Candida auris isolates resistant to three classes of antifungal medications - New York, 2019. MMWR Morb Mortal Wkly Rep. 69:6–9. DOI: 10.15585/mmwr.mm6901a2. PMID: 31917780. PMCID: PMC6973342.

52. Zhu YC, Barat SA, Borroto-Esoda K, Angulo D, Chaturvedi S, Chaturvedi V. 2020; Pan-resistant Candida auris isolates from the outbreak in New York are susceptible to ibrexafungerp (a glucan synthase inhibitor). Int J Antimicrob Agents. 55:105922. DOI: 10.1016/j.ijantimicag.2020.105922. PMID: 32092395.

53. O'Brien B, Liang J, Chaturvedi S, Jacobs JL, Chaturvedi V. 2020; Pan-resistant Candida auris: New York subcluster susceptible to antifungal combinations. Lancet Microbe. 1:e193–4. DOI: 10.1016/S2666-5247(20)30090-2. PMID: 35544199.

54. Iguchi S, Itakura Y, Yoshida A, Kamada K, Mizushima R, Arai Y, et al. 2019; Candida auris: a pathogen difficult to identify, treat, and eradicate and its characteristics in Japanese strains. J Infect Chemother. 25:743–9. DOI: 10.1016/j.jiac.2019.05.034. PMID: 31257156.

55. Garcia-Bustos V, Salavert M, Ruiz-Gaitán AC, Cabañero-Navalon MD, Sigona-Giangreco IA, Pemán J. 2020; A clinical predictive model of candidaemia by Candida auris in previously colonized critically ill patients. Clin Microbiol Infect. 26:1507–13. DOI: 10.1016/j.cmi.2020.02.001. PMID: 32061792.

56. van Schalkwyk E, Mpembe RS, Thomas J, Shuping L, Ismail H, Lowman W, et al. 2019; Epidemiologic shift in candidemia driven by Candida auris, South Africa, 2016-20171. Emerg Infect Dis. 25:1698–707. DOI: 10.3201/eid2509.190040. PMID: 31441749. PMCID: PMC6711229.

57. Kullberg BJ, Arendrup MC. 2015; Invasive candidiasis. N Engl J Med. 373:1445–56. DOI: 10.1056/NEJMra1315399. PMID: 26444731.

58. Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, et al. 2012; Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis. 54:1110–22. DOI: 10.1093/cid/cis021. PMID: 22412055.

59. Kenters N, Kiernan M, Chowdhary A, Denning DW, Pemán J, Saris K, et al. 2019; Control of Candida auris in healthcare institutions: outcome of an International Society for Antimicrobial Chemotherapy expert meeting. Int J Antimicrob Agents. 54:400–6. DOI: 10.1016/j.ijantimicag.2019.08.013. PMID: 31419480.

60. Biswal M, Rudramurthy SM, Jain N, Shamanth AS, Sharma D, Jain K, et al. 2017; Controlling a possible outbreak of Candida auris infection: lessons learnt from multiple interventions. J Hosp Infect. 97:363–70. DOI: 10.1016/j.jhin.2017.09.009. PMID: 28939316.

61. United States Environmental Protection Agency. List P: antimicrobial products registered with EPA for claims against Candida auris. https://www.epa.gov/pesticide-registration/list-p-antimicrobial-products-registered-epa-claims-against-candida-auris. (Updated on 1 March 2022).

62. United States Environmental Protection Agency. List K: EPA's registered antimicrobial products effective against Clostridium difficile spores. https://www.epa.gov/pesticide-registration/list-k-epas-registered-antimicrobial-products-effective-against-clostridium. (Updated on 23 February 2021).

63. Abdolrasouli A, Armstrong-James D, Ryan L, Schelenz S. 2017; In vitro efficacy of disinfectants utilised for skin decolonisation and environmental decontamination during a hospital outbreak with Candida auris. Mycoses. 60:758–63. DOI: 10.1111/myc.12699. PMID: 28872735.

64. de Groot T, Chowdhary A, Meis JF, Voss A. 2019; Killing of Candida auris by UV-C: importance of exposure time and distance. Mycoses. 62:408–12. DOI: 10.1111/myc.12903. PMID: 30748018. PMCID: PMC6850319.